Table 3.
Previous medication in patients infected with tcdA-positive tcdB-positive (A+B+) strains of Clostridium difficile and with tcdA-negative tcdB-positive (A-B+) strains
| A+B+ (n = 101) | A-B+ (n = 21) | P value a | ||
|---|---|---|---|---|
| Medication | ||||
| PPI |
N (%) |
35 (34.7) |
6 (28.6) |
0.800 |
| H2 blockers |
N (%) |
49 (48.5) |
8 (38.1) |
0.474 |
| Probiotics |
N (%) |
49 (48.5) |
13 (61.9) |
0.339 |
| Steroids |
N (%) |
37 (36.6) |
7 (33.3) |
1.000 |
| Chemotherapy |
N (%) |
12 (11.9) |
3 (14.3) |
0.722 |
| Antibiotics | ||||
| All-DDD |
Mean (SD) |
25.4 (18.91) |
27.0 (21.83) |
0.989 |
| Days of antibiotic use |
Mean (SD) |
18.7 (12.25) |
16.6 (12.23) |
0.317 |
| Antibiotics use | ||||
| Fluoroquinolones |
N (%) |
46 (45.5) |
14 (66.7) |
0.096 |
| 2nd Quinolones |
N (%) |
22 (21.8) |
8 (38.1) |
0.161 |
| 3rd Quinolones |
N (%) |
34 (33.7) |
9 (42.9) |
0.458 |
| Clindamycin |
N (%) |
17 (16.8) |
11 (52.4) |
0.001 |
| ESC |
N (%) |
57 (56.4) |
11 (52.4) |
0.811 |
| BL/BLI |
N (%) |
36 (35.6) |
6 (28.6) |
0.620 |
| Carbapenem |
N (%) |
10 (9.9) |
2 (9.5) |
1.000 |
| Glycopeptides |
N (%) |
20 (19.8) |
2 (9.5) |
0.360 |
| Metronidazole |
N (%) |
29 (28.7) |
3 (14.3) |
0.275 |
| Antibiotics dose |
|
|
|
|
| Fluoroquinolones |
Mean (SD) |
5.606 (9.2145) |
7.138 (10.0394) |
0.202 |
| 2nd Quinolones |
Mean (SD) |
1.858 (5.1504) |
2.210 (4.7322) |
0.168 |
| 3rd Quinolones |
Mean (SD) |
3.737 (7.2372) |
4.929 (9.3117) |
0.484 |
| Clindamycin |
Mean (SD) |
1.111 (3.1081) |
4.302 (5.1853) |
<0.0001 |
| ESC |
Mean (SD) |
5.260 (7.7728) |
3.595 (4.5188) |
0.611 |
| BL/BLI |
Mean (SD) |
3.825 (9.2440) |
3.536 (8.2533) |
0.611 |
| Carbapenem |
Mean (SD) |
0.636 (3.3368) |
0.524 (1.7210) |
0.995 |
| Glycopeptides |
Mean (SD) |
1.255 (3.4253) |
0.548 (1.9359) |
0.270 |
| Metronidazole | Mean (SD) | 2.850 (6.9772) | 1.397 (3.7901) | 0.194 |
A+B+, tcdA-positive tcdB-positive strain; A-B+, tcdA-negative tcdB-positive strain; PPI, proton pump inhibitor; DDD, defined daily dose; ESC, extended-spectrum cephalosporins; BL/BLI, beta-lactam/beta-lactamase inhibitor.
a From Fisher’s exact test for categorical variables or the Mann–Whitney U-test for continuous variables.